Expert Perspectives

Sep 24, 2021| Posted in: Hematologic Disorders, News, Regulations, Treatment

FDA Approves Ruxolitinib to Treat Chronic GVHD

The FDA has approved ruxolitinib (Jakafi)  to treat…
Sep 23, 2021| Posted in: Congenital And Genetic Conditions, Drug Development, Neurology/Nervous System Diseases

 Targeted Therapy for Huntington Disease

Michael Panzara, MD at Wave Life Sciences explains…
Sep 22, 2021| Posted in: Cancers, Hematologic Disorders, Treatment

Factors That Impact Treatment Decisions in Elderly Individuals With AML

Dr. Melissa Loh discusses the many factors that…
Sep 21, 2021| Posted in: Cancers, Drug Development, Hematologic Disorders

Will Cilta-Cell Be the Next CAR T-Cell Approval in Multiple Myeloma?

Saad Usmani, MD at Levine Cancer Institute discusses…
Sep 17, 2021| Posted in: Neurology/Nervous System Diseases

What is Lennox-Gastaut Syndrome?

Tracy Dixon-Salazar, PhD, Executive Director of the Lennox-Gastaut…

Rare Disease Clinical Trials CME Program

Learn about clinical trials and rare diseases through these brief courses that are certified for CME and CNE credit.
  • Heather Lau, MD, MS, NYU School of Medicine, New York, NY
  • Morie A Gertz, MD, Mayo Clinic, Rochester, MN
  • Timothy Craig, DO, Penn State University, Hershey, PA
  • Eric T. Wong, MD, Harvard Medical School, Boston, MA

Tenosynovial Giant Cell Tumor (TGCT)

Tenosynovial giant cell tumor (TGCT) is a non-malignant tumor involving the joint synovium, bursae, and tendon sheath. These rare tumors are sometimes referred to as giant cell tumor of the tendon sheath (GCT-TS) and/or pigmented villonodular synovitis (PVNS).

CME Program: Gaucher Disease Highlights from WORLDSymposium 2020

Neal Weinreb, MD, FACP highlights the latest information about Gaucher disease from WORLDSymposium and provides expert analysis of its clinical relevance to help health care providers better care for patients with this rare disease.

WHIM Syndrome Learning Center

WHIM syndrome is a rare, congenital primary immunodeficiency disorder associated with severe neutropenia that affects all ages. However, due to the heterogeneous presentation of the disease, coupled with lack of awareness of the condition, the diagnosis may be delayed, sometimes even into adulthood.

CME Program: Fabry Disease Highlights from WORLDSymposium 2020

Ozlem Goker-Alpan, MD highlights the latest Fabry disease information from the WORLDSymposium and provides expert analysis of its clinical relevance for members of the care team in order to help them care for patients with this rare disease.

CME Program: Mucopolysaccharidoses (MPSs) Highlights from WORLDSymposium 2020

Barbara K. Burton, MD highlights the latest information about MPSs from WORLDSymposium and provides expert analysis of its clinical relevance for members of the care team in order to help them care for patients with these rare diseases.

CME Program: Managing Individuals With Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Michael E. Wechsler, MD, MMSc provides an overview of Eosinophilic Granulomatosis with Polyangiitis (EGPA) – including how to shorten individuals’ diagnostic journey and the time till they access effective therapy – through these brief courses that are certified for CME credit.

TTR Amyloidosis CME Program

Morie A Gertz, MD, MACP provides an overview of TTR Amyloidosis – including how to shorten individuals’ diagnostic journey and the time till they access treatment which might improve their quality of life or even prevent disease progression – through these brief courses that are certified for CME credit.

Spinal Muscular Atrophy CME Program

Nancy L. Kuntz, MD, FAAN discusses diagnosing and managing people with spinal muscular atrophy through these brief courses that are certified for CME and CNEcredit.

Disease Categories

Topics